Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
Portfolio Pulse from Vandana Singh
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented mixed results from the KARDIA-2 Phase 2 study of zilebesiran for hypertension, showing efficacy with indapamide and amlodipine but not with olmesartan. Despite this, analysts from JMP Securities and William Blair express confidence in the drug's potential, recommending ALNY shares with an Overweight rating and a price target of $217. Alnylam, in partnership with Roche Holdings AG (OTC:RHHBY), is advancing zilebesiran into further trials. ALNY shares rose 2.46% to $157.34.
April 08, 2024 | 6:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals Inc. presented mixed trial results for zilebesiran but received positive analyst ratings and a price target of $217. Shares rose 2.46% to $157.34.
The mixed trial results for zilebesiran might have been a concern, but the strong support from analysts, including an Overweight rating and a high price target, likely contributed to the positive stock price movement. The advancement into further trials and the potential market size for the drug also add to the positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Roche Holdings AG, in partnership with Alnylam Pharmaceuticals, is advancing zilebesiran into further trials, indicating a strong commitment to the drug's development.
Roche Holdings AG's partnership with Alnylam for the development of zilebesiran, despite mixed trial results, demonstrates confidence in the drug's potential. This collaboration could positively impact Roche's stock in the short term as it highlights the company's active role in developing promising new treatments.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80